Based on the clinical importance of integrins in NSCLC cells (Figure 1A), we examined their signaling roles through their key downstream effector, focal adhesion kinase (FAK) in A549 cells, which carried EGFR amplification and the KRAS mutation (G12 → S). This evidence concerns the gene KRAS and non-small cell lung carcinoma.